VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > 🌟 Post-Event Highlights from AEPC 2024 in Porto! 🌟

<< Previous

Bullboard Posts

Next >>

Post by jopatcloon May 11, 2024 12:09pm

138 Views

Post# 36035222

🌟 Post-Event Highlights from AEPC 2024 in Porto! 🌟

Very good post

Post-Event Highlights from AEPC 2024 in Porto!

Ventripoint Diagnostics Ltd. Shines as the Star of the Show
What an exhilarating experience at AEPC 2024! We are immensely proud to have showcased our advanced AI-powered heart-scanning software, VMS+4.0, which became the talk of the conference. Thank you to everyone who joined us in Porto for your enthusiasm and engaging discussions.

Key Takeaways from AEPC 2024:
VMS Strain and Heat Maps: Our demonstrations highlighted how VMS+4.0’s visualization tools, especially the strain and heat maps, provide unparalleled insights into heart function. Cardiologists from around the globe were impressed by the precision and detail our software brings to cardiac diagnostics.

Automated Plotting of Key Anatomical Landmarks: Attendees experienced firsthand how VMS+4.0 simplifies and enhances cardiac assessments. The elimination of manual plotting not only streamlines the diagnostic process but also increases accuracy and reliability in volumetric measurements.

The feedback has been overwhelmingly positive, reinforcing our belief that VMS+4.0 will revolutionize cardiac care by making advanced diagnostics quicker and more accessible.

Moving Forward:
As we continue to await FDA approval, our resolve to deliver VMS+4.0 to healthcare providers worldwide has only strengthened. The interest and inquiries from international cardiologists and healthcare institutions at AEPC have been inspiring.

Ventripoint: The New Standard in Cardiac Imaging
With VMS+4.0, we're not just following trends – we're setting them. Our technology stood out as a beacon of innovation and practicality, proving that we are at the forefront of medical technology.

Thank you again for making us the star of AEPC 2024! We look forward to bringing our cutting-edge solutions to your hospitals and clinics.

Ventripoint HeartHealth MedicalInnovation AI FDA Cardiology AEPC2024 PostAEPC

Special thanks to the Ventripoint Diagnostics Ltd. team, the Angiopro GmbH team GmbH, the CardioLogic Ltd team, the President of the AEPC, Dr. Nico Blom, Dr. Kai Thorsten Laser, and the participants of the VMS+ workshop, Tineke Willems and so many others for their interest and time at our booth.

For ongoing updates or to get in touch, continue to follow our journey!